GLOBAL PROJECT DELIVERY

MENA · Africa · Central Asia · Europe · Americas

Direct investor desk ↗
Home/ Projects/ Blood Bank Facility
Healthcare facilities · INVESTOR TECHNICAL BRIEF

Blood Bank Facility

Donor recruitment, collection, component processing, testing, storage and traceable distribution in one controlled service.

Request feasibility study ↗
Indicative CAPEX
USD 1.2–6M
Delivery period
8–14 months to operational qualification and supervised service launch
Installed capacity
Tier 1: 20,000–60,000 donations/year
Regulatory endpoint
National blood-service licence, donor/traceability rules and quality-system readiness; ISO 15189 may apply to testing laboratories
01

What the facility produces and why it matters locally

Donor recruitment, collection, component processing, testing, storage and traceable distribution in one controlled service. The investment case is tested against import dependency, procurement demand, supply resilience, attainable local content and regional export access. Portfolio definition precedes equipment selection so capital is not locked into an incompatible process.

02

Indicative capital band

USD 1.2–6M. The range covers core equipment, controlled environments, process utilities, installation, qualification, technology transfer and initial training at the stated tier. Preliminary engineering range; excludes land, finance cost, taxes and import duty. Final scope and price are confirmed at the feasibility gate.

03

Footprint and clean environment

500–2,200 m² gross with segregated donor, processing, testing, quarantine, released storage and dispatch areas.

Blood banks generally use controlled hygienic zoning rather than classified cleanrooms. Component processing, testing and storage are separated with validated temperature and contamination controls.

04

Programme from design basis to operation

01 Feasibility & design basis02 Architecture & process engineering03 Infrastructure & clean environment04 Equipment procurement and FAT05 Installation, SAT and qualification06 Process validation and training07 Operational handover

8–14 months to operational qualification and supervised service launch. Permit, authority review, civil-condition, customs and client approval delays sit outside the base programme unless expressly contracted.

05

Installed capacity tiers

Tier 1: 20,000–60,000 donations/year; Tier 2: 100,000–250,000/year; operating days and collection network dependent.

Capacity assumes qualified materials, stated shifts, planned maintenance and validated yield; it is not the sum of nominal machine speeds.

06

Process flow and utilities

Core process

  • Donor registration, screening and phlebotomy
  • Component separation and expression
  • Infectious-disease and immunohaematology testing
  • Quarantine and controlled release
  • Temperature-controlled component storage
  • Traceable issue, transport and haemovigilance

Site and utilities

Redundant power, UPS, emergency generation, temperature-mapped cold rooms/equipment, HVAC, secure data systems, infectious waste and validated transport.

07

Regulatory and quality endpoint

National blood-service licence, donor/traceability rules and quality-system readiness; ISO 15189 may apply to testing laboratories. Typical readiness: 8–14 months.

Infinity IVD delivers the contracted facility, QMS, validation and dossier work. Certification or market authorisation is granted only by the competent independent authority.

08

Staffing and transfer of know-how

Indicative 20–90 FTE including physicians, nurses/phlebotomists, laboratory scientists, quality and cold-chain personnel; 6–12 weeks systems and workflow training.

09

Equipment classes and procurement boundary

  • Donor chairs, mixers and tube sealers
  • Refrigerated blood-bag centrifuges and plasma extractors
  • Blood grouping and infectious-disease testing
  • 2–6°C refrigerators, plasma freezers and platelet agitators
  • Temperature monitoring and blood-bank software

The feasibility equipment register identifies supplied equipment, client-supplied items, spares, initial consumables, FAT/SAT responsibility, calibration and qualification ownership.

10

Critical process risks and operating economics

  • Donor/sample identification error
  • Cold-chain excursion
  • Infectious screening or release failure
  • Component yield/quality loss
  • Traceability and haemovigilance breakdown

Operating economics are issued as a sensitivity model using local labour, utilities, materials, yield, utilisation and financing assumptions; they are not a guaranteed return.

11

Relevant delivery evidence

  • Azerbaijan — blood-bank equipment and workflow programme
  • Türkiye — blood-bank systems portfolio

Client names and photography are disclosed only with permission; confidential programmes retain a technical envelope rather than an invented attribution.

Review programme evidence ↗
Project desk